Comparative Pharmacology
Head-to-head clinical analysis: BRIELLYN versus LEVONEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIELLYN versus LEVONEST.
BRIELLYN vs LEVONEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.
None Documented
None Documented
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
The terminal elimination half-life is approximately 24-30 hours. This relatively long half-life supports once-daily dosing and allows for stable plasma concentrations within 5-7 days of continuous use.
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Renal excretion of conjugated metabolites accounts for approximately 60-80% of an administered dose; fecal elimination via bile accounts for 20-40%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive